Alvocidib

Alvocidib
Names
	IUPAC name 2′-Chloro-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]flavone
	Systematic IUPAC name 2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-1-benzopyran-4-one
	Other names Flavopiridol, HMR 1275, L-868275
Identifiers
CAS Number	146426-40-6 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:47344 ;
ChEMBL	ChEMBL428690 ;
ChemSpider	4450222 ;
DrugBank	DB03496 ;
IUPHAR/BPS	5680;
KEGG	D09868;
MeSH	Flavopiridol
PubChem CID	5287969;
UNII	45AD6X575G ;
CompTox Dashboard (EPA)	DTXSID20904970 ;
	InChI InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1 Key: BIIVYFLTOXDAOV-YVEFUNNKSA-N ;
	SMILES Clc4ccccc4C=2Oc1c(c(O)cc(O)c1C(=O)C=2)[C@H]3CCN(C)C[C@H]3O;
Properties
Chemical formula	C21H20ClNO5
Molar mass	401.8402
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Alvocidib (INN; also known as flavopiridol) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation. The target of alvocidib is the positive transcription elongation factor P-TEFb. Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production.

The compound is a synthetic analog of natural product rohitukine which was initially extracted from Aphanamixis polystachya (formerly Amoora rohituka, hence the name) and later from Dysoxylum binectariferum.